venBio
View Older Stories View More Recent Stories
-
Form SC 13G/A Lion Biotechnologies, Filed by: venBio Select Advisor LLC
-
Form SC 13G/A Mirati Therapeutics, Filed by: venBio Select Advisor LLC
-
Form SC 13G ALIMERA SCIENCES INC Filed by: venBio Select Advisor LLC
-
Form SC 13G Oncobiologics, Inc. Filed by: venBio Select Advisor LLC
-
Immunomedics Announces Second Quarter Fiscal 2017 Results and Clinical Program Developments
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Immunomedics Strongly Encourages Stockholders to Reject the venBio Nominees — With Four New Independent Directors and a Robust Value-Maximization Process, Stockholders Should Not Risk Giving venBio
-
Glass Lewis Endorses Full Slate of venBio Nominees at Immunomedics
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
ISS Endorses Full Slate of venBio Nominees at Immunomedics
-
Immunomedics Mails Letter to Stockholders Highlighting Strength of New Board and Deep Engagement in Robust, Value-Creating Strategic and CMC Processes
-
OrbiMed Comments on Immunomedics Proxy Contest
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Immunomedics Sets the Record Straight in New Presentation
-
venBio Calls on Immunomedics Stockholders to Support Meaningful Change
-
Immunomedics Issues Statement to Stockholders and Files Investor Presentation
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
venBio Releases Presentation Detailing Urgent Case for Change at Immunomedics
-
Immunomedics Mails Letter to Stockholders
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
venBio Sends Letter to Immunomedics Stockholders
-
Immunomedics to Mail Letter to Stockholders Highlighting Unprecedented Progress Toward Enhanced Value Creation
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
venBio Sends Letter to Immunomedics Stockholders
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
venBio Responds to Immunomedics Announcement
-
Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan
-
Form DEFC14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Impel NeuroPharma Announces $36M Funding to Advance Novel Drug Delivery Platform for Central Nervous System Disorders
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Form PRRN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
venBio Responds to Immunomedics’ Postponement of Annual Meeting
-
Immunomedics (IMMU) Announces Postponement of Annual Meeting of Stockholders
-
Immunomedics Postpones 2016 Annual Meeting of Stockholders
-
Form DFAN14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
venBio Comments on its Recent Nomination of Four Highly-Qualified Candidates for Board of Immunomedics, Inc.
-
Immunomedics Comments on Receipt of Director Nominations
-
UPDATE: Immunomedics (IMMU) Shares Pop to Session Highs Following venBio 13D Filing
-
Form SC 13D IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Form PREC14A IMMUNOMEDICS INC Filed by: venBio Select Advisor LLC
-
Form 13F-HR venBio Select Advisor For: Sep 30
-
Form D/A venBio Select Fund Ltd.
-
Form D/A venBio Select Fund LLC
-
Heart Metabolics Announces Initiation Of Phase 2b Study Of Perhexiline For Hypertrophic Cardiomyopathy
-
Heart Metabolics Announces Initiation Of Phase 2b Study Of Perhexiline For Hypertrophic Cardiomyopathy
-
Form 13F-HR venBio Select Advisor For: Jun 30
-
Heart Metabolics Adds New Board Member And Expands Senior Management Team
-
Form 13F-HR venBio Select Advisor For: Mar 31

